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Abstract
Immunosuppression contributes significantly to the caseload of visceral leishmaniasis (VL).
HIV coinfection, solid organ transplantation, malnutrition, and helminth infections are the
most important immunosuppression-related factors. This review briefly describes the chal-
lenges of these associations. East Africa and the Indian subcontinent are the places where
HIV imposes the highest burden in VL. In the highlands of Northern Ethiopia, migrant rural
workers are at a greater risk of coinfection and malnutrition, while in India, HIV reduces the
sustainability of a successful elimination programme. As shown from a longitudinal cohort in
Madrid, VL is an additional threat to solid organ transplantation. The association with malnu-
trition is more complex since it can be both a cause and a consequence of VL. Different
regimes for therapy and secondary prevention are discussed as well as the role of nutrients
on the prophylaxis of VL in poverty-stricken endemic areas.
Introduction
Immunosuppression is associated with leishmaniasis. It is more frequently described in associa-
tion with visceral leishmaniasis (VL) as it is one of the consequences of the disease, especially in
the latter stages. VL occurs both in the ‘Old World’ and in the ‘New World’, often in underre-
sourced areas of conflict and instability. The causative agents of VL are those in the Leishmania
donovani–L. infantum complex. However, other species of Leishmania that cause cutaneous or
mucocutaneous leishmaniasis have also been described as resulting in immunosuppression.
Immunosuppression in leishmaniasis may stem from the leishmanial infection itself, but it
can be further exacerbated by comorbidities involving coinfections with pathogens, such as
Human Immunodeficiency Virus (HIV) and helminths, or through morbidity associated with
malnutrition.
Methods
Treatment of VL is difficult in patients with certain comorbidities. This paper, developed after
deliberations at a session on the subject at the WorldLeish 2017, discusses the value of
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antiretroviral treatment (ART) in VL–HIV patients, illustrates the contrasting picture of VL–
HIV in East Africa and Asia, examines VL in immunosuppressed patients after transplanta-
tion, and considers the need for nutritional supplements as a treatment adjunct in VL-endemic
countries with widespread malnutrition. We elaborate on how immunosuppression due to
HIV coinfection and malnutrition exacerbates the symptoms of VL as well complicates treat-
ment. We illustrate the many things that we do not understand to date but also other things
where there remains a ‘know–do gap’, a gap between evidence and effective implementation.
Results
Helminths
Experimental coinfection with Schistosoma mansoni and L. donovani in mice showed that
those with established S. mansoni infections fail to control L. donovani growth in the liver and
spleen [1]. The influence of helminth coinfection on cutaneous leishmaniasis has also been
presented in a number of studies but with conflicting results, which may be because the impact
of helminth coinfection on leishmanial lesion growth appears to be time dependent [2].
Furthermore, helminth infections have been reported to influence the clinical course and
the immune response to cutaneous leishmaniasis caused by L. braziliensis. Patients with L. bra-
ziliensis coinfected with helminths healed at a slower rate compared to patients without coin-
fection, suggesting a role for screening and treatment of helminths to improve the outcomes of
L. braziliensis treatment and potentially reduce the risk of progression to mucosal disease [3].
However, subsequent randomised clinical trials showed that treating helminths did not make
a difference in treatment outcomes [4].
HIV
HIV infection has been shown to appreciably increase the risk of developing VL in endemic
areas, reduce the chances for adequate therapeutic response, and greatly increase the likelihood
of relapse. In vitro studies showed that the addition of HIV to human mononuclear cell cul-
tures altered the T helper cell cytokines induced in response to L. donovani stimulation [5].
Subsequent studies in Ethiopian HIV-coinfected VL patients demonstrated that the out-
come of both conditions was worsened, with enhanced severity of the VL and acceleration of
HIV progression.
The current picture of VL seen in East Africa and that in Asia differ considerably, with the
picture in India, Nepal, and Bangladesh moving towards elimination of VL as a public health
problem based on political commitment coupled with focused studies aimed at improving
treatment. The measures taken in this elimination agenda has led to improved surveillance
and, in turn, better identification of VL–HIV.
VL–HIV coinfection in East Africa
East Africa has an estimated VL caseload of around 30,000 cases annually. Several areas face
high rates of HIV coinfection. This is most marked in Northwestern Ethiopia, where coinfec-
tion rates of approximately 20% have been reported [6]. In part, this relates to the high number
of young seasonal workers migrating to the area from VL-nonendemic highlands [6].
As in the rest of the world, the standard of care for VL–HIV coinfected patients in East
Africa consists of several components. Besides aiming to achieve parasitologically confirmed
VL cure, early initiation of ART is vital. This should be followed by secondary prophylaxis, tar-
geting those at highest risk of VL relapse [6].
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Within East Africa, the first-line treatment in HIV-negative patients consists of parenteral
administration of antimonials and paromomycin for 17 days. Overall, this combination ther-
apy was found effective and safe, although the daily intramuscular injections can be painful
[6]. For HIV patients, WHO guidelines recommend liposomal amphotericin B at a total dose
of 40 mg/kg [7]. Although there are a number of commercially available preparations of lipidic
and liposomal formulations of amphotericin B available, at present, the only liposomal prepa-
ration procured for use in VL by WHO is the liposomal formulation AmBisome (Gilead Sci-
ences; San Dimas, California, United States of America). There are a number of noninferiority
studies ongoing with other preparations; however, to date, safety and effectiveness results have
not been encouraging [8]. Additionally, the lack of a clear regulatory pathway for the registra-
tion of these other formulations complicates the entry of new competitors on the markets [8].
As such, outside of nongovernmental organisation (NGO) settings, availability is often
limited.
Regarding treatment of VL in HIV-positive patients, most drugs have proven disappointing
(Table 1). The Me´decins Sans Frontières (MSF) experience with a combination regimen con-
sisting of AmBisome (Gilead Sciences; San Dimas, California, USA) 30 mg/kg and miltefosine
for 28 days looks promising, with initial cure rates of 81% [6]. Based on this experience, Drugs
for Neglected Diseases initiative (DNDi) is conducting a randomised controlled trial with two
arms: (1) AmBisome 30 mg/kg combined with miltefosine for 28 days and (2) AmBisome 40
mg/kg in monotherapy [9]. Data are expected to be reported soon.
Several studies from Ethiopia have shown the importance of ART initiation in VL–HIV
coinfected patients to reduce mortality and relapse rates [6, 16]. However, studies looking at
ART uptake in routine programme conditions are lacking. In a retrospective patient file review
conducted in Northern Ethiopia, ART uptake—defined as documented proof of ART
Table 1. Overview of current evidence related to different aspects of VL–HIV care in East Africa.
Objective Status: Experience in Northwestern Ethiopia
Achieving parasitological cure Antimonials: toxicity, suboptimal efficacy [10]
Miltefosine: safe but limited efficacy [11]
AmBisome 30 mg/kg: safe but limited efficacy [12]
• Initial treatment cure rate of 74% in primary VL and 38% in relapsed VL;
overall cure rate 59%
AmBisome 30 mg/kg IV + miltefosine PO for 28 days in compassionate use [6]
• Initial cure rate of 81%
Early ART initiation Retrospective patient file review in one referral and one district hospital in
Northwestern Ethiopia. Amongst newly diagnosed VL–HIV patients, ART
uptake was 28% (13/47) at the district hospital and 61% (30/49) at the referral
hospital [13]
Preventing VL relapse (secondary
prophylaxis)
Single-arm clinical trial evaluating monthly administration of pentamidine 4
mg/kg IV for a minimum of 12 months; a 6-month extension was given for
those with CD4 counts 200 cells/μL by 12 months of pentamidine [6, 14]. No
relapse after pentamidine discontinuation if CD4 counts > 200 cells/μL by 12
months of pentamidine (0/28)
3 out of 17 relapses in those with CD4 counts 200 cells/μL by 12 months,
despite a 6-month pentamidine extension
Preventing primary VL (primary
prophylaxis)
PreLeisH study (Northern Ethiopia): Multicentre observational cohort study
HIV patients in HIV care and living in a VL-endemic area will be followed for
2 years with clinical/laboratory evaluation every 3 months. The incidence of
asymptomatic Leishmania infection will be determined, and a clinical
prediction tool to predict the onset of VL will be developed [15].
Abbreviations: ART, antiretroviral treatment; CD4, cluster of differentiation 4; IV, intravenously; PO, per os (oral
treatment); VL, visceral leishmaniasis.
https://doi.org/10.1371/journal.pntd.0006375.t001
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prescription in VL patients—in newly diagnosed VL–HIV patients was fair (61%) at the refer-
ral-hospital level but poor (28%) at the district hospital [13] (Table 1). This poor uptake could
be due to many factors, including poor documentation and information exchange between
referring and recipient facilities. Another factor is that VL–HIV coinfection predominantly
occurs in highly mobile populations (e.g., seasonal migrants), who might move back to their
place of origin for ART initiation. Alternatively, it is possible that a substantial proportion
become lost to follow-up and never start ART, or with long delays.
Data on secondary prophylaxis of VL in HIV patients in anthroponotic (L. donovani)
areas are limited to a single-arm trial, evaluating the use of monthly administration of pent-
amidine, a drug currently not in use for VL treatment in East Africa. Previously, the out-
comes at 12 months of pentamidine use supporting the effectiveness, safety, and feasibility
of this intervention have been reported [17]. Data on the risk of relapse after discontinuing
12 months of pentamidine have been published recently [6, 14]. For those reaching a clus-
ter of differentiation 4 (CD4) count > 200 cells/μL at 12 months, no relapses were seen
(Table 1). Those with a CD4 count 200 cells/μL remained at risk, suggesting that pentam-
idine continuation might be needed on a case-by-case basis until CD4 count levels have
increased. The overall risk of VL relapse was 37% by 2 years after starting pentamidine,
highest amongst those with low baseline CD4 counts and a history of (multiple) relapses.
The Ethiopian national programme should therefore consider this intervention within
their national guidelines.
An unexplored strategy to reduce the VL–HIV burden would entail the prevention of VL
onset in HIV patients. The PreLeisH study, started in October 2017, aims to provide insights
into the incidence of asymptomatic Leishmania infection in HIV patients living in VL-
endemic areas and the identification of those at highest risk of VL [15]. This would constitute
a first step towards a ‘screen and treat’ strategy [18].
VL–HIV coinfection in Asia
The incidence of VL has been decreasing in Asia over the last decade. India, Nepal, and Ban-
gladesh used to carry over 50% of the global burden of VL; however, reported cases of VL are
now substantially higher in East Africa than in the Indian subcontinent (ISC) [19]. The decline
in cases is most likely due to the elimination efforts because in 2005, the three most affected
countries entered into an agreement to eliminate VL as ‘a public health problem’ by 2015,
which was later extended to 2017. This was considered feasible due to a myriad of factors,
including the assumed purely anthroponotic nature of VL spread in the subcontinent, a single
vector, availability of effective rapid diagnostic tests, and crucially, the availability of short-
course effective treatments [20].
The East Indian state of Bihar has been the epicentre of VL for over a century. This popu-
lous state is also one of the few in India where the rate of new HIV infections is increasing
[21], bringing together two diseases whose interaction is a well-established risk factor for poor
outcomes [22]. However, until recently, there has been a dearth of data and evidence sur-
rounding VL–HIV coinfection in the ISC. A 2014 single-centre study from Bihar reported
5.6% of 2,077 consecutive confirmed VL patients14 years of age were found to be HIV posi-
tive; half of these were unaware of their HIV status [23]. With improved disease surveillance
and reporting, including recommendations to offer all VL patients screening for HIV [20], the
numbers of reported coinfected cases are increasing. With the overall falling incidence of VL,
this means that at a state level, currently up to 7% of all reported VL patients18 years of age
are coinfected with HIV in 2017; however, in highly VL-endemic districts with reliable HIV
screening, this is as high as 20% [24].
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More recently, increasing numbers of coinfected cases are being reported following the
introduction of routine HIV screening in Nepal, where 9 out of 48 VL cases presenting to a ter-
tiary hospital catering to a wide VL-endemic area during 2016–2017 were coinfected with HIV
[24]. Bangladesh remains a lacuna since HIV screening of VL patients has not yet been intro-
duced, even in patients presenting with multiple relapses.
There remains a substantial number of issues in the diagnosis and management of coinfected
patients in the ISC. Although the recombinant K39 (rK39) test has been shown to be highly sensi-
tive and specific for patients not diagnosed with HIV, its accuracy in coinfected patients has not
yet been established in the ISC. Additionally, no high-quality evidence-based treatment regimens
exist for coinfection in the ISC; the current WHO and regional recommendation of 40 mg/kg of
AmBisome over 38 days is based on evidence generated on a different strain (L. infantum) in
southern Europe (Table 2). A clinical trial to establish the safety and effectiveness of this regimen
and that of a shorter lower-dose combination of AmBisome and miltefosine in Bihar is nearing
completion [25]. The main challenges for coinfection in the ISC are presented in Table 3.
Late presentation of coinfected patients poses the most difficult obstacle in improving
patient outcomes. Nearly half present with CD4 counts of under 100, with the majority under
200 [28, 30]. Concomitant infection with TB has become an additional challenge; with the use
of cartridge-based nucleic amplification test (CB-NAAT) screening in VL–HIV coinfected
patients, up to 20% are being identified with tuberculosis (TB) infection. These patients have
the highest risk for mortality [28] and present therapeutic challenges with regards to timing
and monitoring of concurrent treatment initiation (or continuation) for VL, TB, and HIV. As
such, in endemic areas, VL should always be considered in addition to other opportunistic
infections already highlighted by recent WHO guidelines on management of patients present-
ing with advanced HIV disease [27].
In the future, a better understanding of the epidemiology and progression of VL in patients
with HIV through improved proxy biomarkers will be key in improving earlier detection and out-
comes. The susceptibility of L. donovani in the ISC to low-dose liposomal amphotericin B may pro-
vide a unique opportunity for primary prophylaxis in asymptomatic VL–HIV coinfected patients,
potentially reducing progression to symptomatic disease, and should be further explored.
Solid organ transplants (SOTs) and leishmaniasis
The worldwide number of cases of VL in recipients of SOTs has quadrupled since the 1990s,
although VL is still a rare disease among transplant recipients [29]. Most of the clinical cases have
Table 2. Current evidence for treatment of VL–HIV coinfection in the ISC.
Treatment of primary VL–HIV episode Result Limitations/Observations
40 mg/kg of liposomal amphotericin B in 10 divided
doses on days 1–5, 10, 17, 24, 31, and 38
8 out of 10 relapsed within 7 months, 2 out of 10
defaulted. No patients on ART
Prospective cohort study of 10 patients in southern Europe,
pre-ART [26]. No data from ISC available
30 mg/kg AmBisome in 6 divided doses with 100 mg
per day oral miltefosine over 14 days
In patients taking ART, 6.4% relapse, 11.2%
mortality at 12 months
Observational data from Bihar, India [27]
20–25 mg/kg AmBisome in 4–5 divided doses over
4–5 days
In patients taking ART, 16.2% relapse, 8.7%
mortality at 12 months
Observational data from Bihar, India [28]
Treatment of relapses or refractory cases
No evidence base currently exists
Secondary prophylaxis
1 mg/kg amphotericin B deoxycholate or liposomal
amphotericin B
No relapse versus 75% relapse in nonprophylaxis
arm at 6 months
Retrospective study from West Bengal, India [29].
Abbreviations: ART, antiretroviral therapy; ISC, Indian subcontinent; VL, visceral leishmaniasis.
https://doi.org/10.1371/journal.pntd.0006375.t002
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been reported in the Mediterranean Basin, particularly in Spain, which is among the foremost in
performing SOTs and is endemic for L. infantum transmission. In these patients, the immunosup-
pressive therapy to avoid graft rejection affects T cell lymphocytes, altering the mechanisms of
defence against intracellular microorganisms as Leishmania, predisposing to manifestations of
disease. However, the precise mechanism behind the VL risk has not been well defined.
The development of VL by SOT recipients is not related to the origin of the organ, the
socioeconomic category of the patient, nor the type of transplant, although usually associated
with renal transplants as they are the most frequent transplant (Table 4). It is much more
Table 3. Challenges in VL–HIV infection in Asia.
Epidemiological
Limited evidence on prevalence of HIV in reported VL cases in endemic areas
No established method of screening HIV patients in VL-endemic areas for VL
No data on prevalence of asymptomatic VL infection in HIV patients in endemic areas
No data on risk factors for progression from asymptomatic VL infection to symptomatic VL infection in patients
with HIV
Diagnostic
No evidence on the accuracy of existing RDTs for VL in coinfected patients
Standard VL case definition unlikely to be appropriate for VL–HIV coinfected cases
Improved biomarkers for confirming relapse need to be developed to reduce risk of repeated invasive biopsy
Treatment
No evidence for 40 mg/kg WHO recommended dose for VL–HIV infection in ISC
Only observational data for lower doses of AmBisome and combination treatment
No evidence on primary prophylaxis
Limited evidence on secondary prophylaxis
Very limited therapeutic options for treatment of VL in coinfection
Challenge of VL–HIV–TB triple infection emerging and poorly understood
Abbreviations: ISC, Indian subcontinent; RDT, rapid diagnostic test; TB, tuberculosis; VL, visceral leishmaniasis.
https://doi.org/10.1371/journal.pntd.0006375.t003
Table 4. Review of publications reporting cases of leishmaniasis in SOT recipients, describing the organ transplanted and the number of cases and the treatment
options used for each type of leishmaniasis.
Type of leishmaniasis Type of SOT Cases reported References Treatments
Visceral leishmaniasis Kidney 119 [31, 33, 38–58] Primary: AmBisome, Antimonials, Amphotericin B, Allopurinol
Relapses: AmBisome, Miltefosine
Liver 11 [31, 56–60]
Heart 9 [31, 33, 58, 61, 62]
Lung 4 [31, 63, 64]
Pancreas 2 [65, 66]
Visceral and cutaneous Kidney 2 [67, 68] AmBisome B, Antimonials
Liver 1 [69]
Cutaneous leishmaniasis Kidney 5 [70–74] Antimonials, Ambisome B, Allopurinol + fluconazole
Mucocutaneous leishmaniasis Kidney 3 [75–77] Antimonials
Liver 2 [78, 79] Amphotericin B, AmBisome
Asymptomatic leishmaniasis Kidney 42 [35, 80]
Liver 4 [81]
Abbreviation: SOT, solid organ transplant.
https://doi.org/10.1371/journal.pntd.0006375.t004
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dependent on the degree of exposure to infection. The higher incidence of VL in SOT recipi-
ents from Brazil compared to those from Spain has been explained as a consequence of the
higher incidence and transmission of VL in the first place [31].
The recent outbreak of leishmaniasis in Fuenlabrada (southwest Madrid, Spain), with a
mean incidence rate of 22.2 per 100,000 inhabitants in the general population [32], has allowed
the study of a cohort of patients with SOT living in the area [33]. During the outbreak, a total
of 7 VL cases were counted amongst the 68 SOT recipients included in the study, yielding an
annual incidence of 2,997 cases per 100,000 population. This suggests that the susceptibility to
develop VL is 135 times higher in these patients than shown by the immunocompetent indi-
viduals living in the same area. This study also confirms that the degree of exposure to infec-
tion, expressed as the distance from the patient’s residence to the focus of the outbreak, is a key
risk factor, as has already been described for the general population [34]. Further, despite this
higher risk of developing clinical leishmaniasis, Leishmania-specific cellular immunity analysis
of the SOT-recipient cohort demonstrated asymptomatic infection in 12 out of the 57 evalu-
ated, all of whom showed specific lymphoproliferation and interferon gamma (IFN-γ) produc-
tion in response to the parasite antigens. Although the ratio clinical/subclinical appears to be
high, parasite infection does not always lead to overt disease in these transplanted patients
[35].
In SOT recipients, performance of diagnostic tests for VL is variable, and a combined
approach of parasitological and molecular methods is recommended [36] since serological
tests have shown a lower sensitivity [31].
The recommended therapy for VL in transplanted patients is the same as that for immuno-
competent individuals: a total dose of 21 mg/kg of AmBisome; however, other therapies, such
as antimonial, amphotericin b, or allopurinol, have also been used with varying success
(Table 4). Relapse rates in these patients are low and can be resolved with AmBisome or milte-
fosine treatment (Table 4). Secondary prophylaxis is not usually required. The measurement
of the cell-mediated immune response in SOT recipients may help to confirm recovery follow-
ing VL treatment and to assess the risk of relapse and necessity of secondary prophylaxis. Anal-
ysis of Leishmania-specific cell immunity in 5 SOT recipients patients that remained relapse-
free after VL treatment showed positive lymphoproliferation and IFN-γ production after in
vitro cell stimulation [35], in a similar way to that reported for HIV-positive patients after VL
treatment [37].
All these data highlight the need to assess previous exposure to the parasite in patients sub-
jected to induced immunosuppression, to counsel recipients in endemic areas to reduce the
risk of being bitten by sand flies, and to follow up SOT patients in areas with outbreaks of
leishmaniasis.
Malnutrition and leishmaniasis
VL mostly affects poverty-stricken and often malnourished populations. Data from 29,570 VL
patients divided over Brazil, East Africa, Nepal, and India showed that severe malnutrition in
VL is frequent in South Asia and East Africa, while it is uncommon in Brazil [82]. The amasti-
gote form of the Leishmania parasite attacks the reticuloendothelial system of naive people and
causes an infection that either spontaneously resolves (in 90% of patients) or progresses over
weeks to months to clinical VL and death, if untreated. Progression to disease depends on the
condition of the host; genetic factors, immune suppression, malnutrition, and the presence of
other infectious diseases all play a role [83, 84]. Observational studies have suggested that both
protein malnutrition and micronutrient deficiencies may speed the progression of leishmania-
sis infection [85, 86] and that VL itself worsens malnutrition [87, 88].
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Protein malnutrition and VL. In a murine model of moderate childhood malnutrition,
poly-nutrient deficiency led to a 4–5-fold increase in early visceralisation of L. donovani
following infection and a 16-fold decrease in lymph node barrier function [89], while in a
recent study in hamsters infected with L. infantum, well-nourished hamsters had stronger
specific immune responses and lower parasite loads than their malnourished counterparts
[90]. Hence, it is likely that malnourished people will have a greatly increased risk of devel-
oping VL. Indeed, in a study in Brazil, the parasite burden in children with severe and
moderate malnutrition was almost three times higher than in nonmalnourished children
[91].
Micronutrients and VL. Deficiencies of micronutrients such as iron, iodine, zinc, and
vitamin A are known as ‘hidden hunger’ and in developing countries often go hand in hand
with acute malnutrition. The poverty-stricken populations affected by VL habitually eat large
amounts of staple food crops (maize, wheat, rice) high in calories but lacking sufficient micro-
nutrients, leaving them susceptible to disease. In a study aiming to understand the link
between micronutrient deficiencies and VL in Bangladesh, it was found that in a population
with poor nutritional status, retinol and zinc levels were lower and C-reactive protein levels
higher in patients who developed VL compared to those who remained symptomless after
infection [92].
The reality in the field: Nutritional support for VL patients. Supportive treatment, like
nutritional supplementation, before the start of therapy of VL is recommended both by WHO
[7] and in national VL guidelines in most endemic countries. Ready-to-use therapeutic food
(RUTF) is available in most hospitals in VL-endemic regions as part of well-financed pro-
grammes for the control of TB and HIV. But since VL remains a neglected disease, in practice,
VL patients do not receive any nutritional therapy, unless they are less than five years of age
and included in UNICEF programmes, coinfected with HIV and/or TB, or specifically sup-
ported by NGOs.
Populations affected by VL frequently suffer from malnutrition, including micronutrient
deficiencies. Clinical experience suggests that VL patients recover more quickly with nutri-
tional supplementation. There is a need of advocacy to governments and donors to understand
the importance of nutrition in VL and include nutritional supplements as part of VL treat-
ment. In Africa, RUTF, which is currently only used in TB and HIV programmes, needs to be
available for VL patients as well. There is a need for policy change; WHO and partners should
advocate for free nutritional support for VL patients to other agencies such as UNICEF or the
World Food Programme (WFP).
Documenting malnutrition in VL is crucial for measuring the problem and acting, but VL
control programmes often do not collect any anthropometric data. WHO has recently
included anthropometric indicators as part of the global VL surveillance system and recom-
mends countries to collect data on weight and height of all VL patients.
In a recent Cochrane protocol review [93] assessing the effects of oral nutritional supple-
ments in people being treated with antileishmanial drug therapy for VL, the authors found no
completed or ongoing studies. This absence of evidence should not be interpreted as the evi-
dence of no effect for nutritional supplements in people with VL. It means that eligible
research for this review has not been identified.
Discussion
Special attention should be paid to immunosuppression among persons at risk of exposure to
the viscerotropic species of Leishmania in the ISC and East Africa and L. infantum scattered in
Central Asia, the Middle East, Mediterranean Basin, and Latin America.
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HIV-infected individuals, SOT patients (and, by extension, those taking immunosuppres-
sive medications for other reasons), and malnourished populations are the most vulnerable.
They may have a much higher risk of developing disease after being infected as compared to
immunocompetent individuals.
Given the reliance on rK39 rapid diagnostic tests (RDTs) in many settings and given the
poorer performance of serological testing in immunosuppressed patients, alternative noninva-
sive diagnostic methods, such as molecular testing or antigen detection, should be evaluated in
immunosuppressed patients and adapted for field use. Such tests might also be better suited to
monitor treatment response and to diagnose relapses.
Due to the clearer relationship and higher number of affected patients, HIV infection is the
most critical threat. Migrant crop workers in Ethiopia pose a challenge due the temporal work
that raises hurdles to HIV adherence and secondary prophylaxis for VL. Despite the rewarding
efforts to control the transmission of VL in the ISC, there remains a substantial number of
coinfected patients. Since patients with CD4 counts under 200 cells/mm3 appear to be at a
higher risk of relapse, earlier diagnosis of HIV infection, specific biomarkers of relapse, and
the development of improved treatment regimens and options for secondary prophylaxis are
urgently needed. In Africa, monthly pentamidine and elsewhere weekly or biweekly liposomal
amphotericin B, potentially combined with miltefosine, are the most promising regimes.
The VL epidemic in the urban settlement in Fuenlabrada, Madrid, showed clearly that VL
can become an urban disease and poses an extremely high risk of disease among immunocom-
promised individuals living in the proximity of VL foci. Testing for exposure to Leishmania,
preventing sand fly bites, and careful follow-up are measures that can reduce the harm of VL
in solid transplant patients.
The effect of immunosupression caused by malnutrition needs to be studied more carefully,
since most severely or moderately malnourished patients live in the most VL-affected, pov-
erty-stricken regions. Malnutrition appears to be simultaneously a risk for the development of
VL after infection and a consequence of the disease, possibly as part of the acute phase reaction
of VL. Addressing nutrition in populations not covered by nutritional supplementation that
are at risk of VL should be implemented. Studies on the specific components of nutrition asso-
ciated with the risk of VL development, as well as their role as adjuvant therapy for patients,
are needed.
This review has shown that the main impact of immunosuppression in persons exposed to
Leishmania is increased risk of development of disease after exposure, higher risk of death, and
relapse. While it is highly likely that Leishmania infection leads to parasite persistence due to
the absence of sterilising immunity and that T-cell immune response impairment is the princi-
pal mechanism behind evolution of disease, the detailed mechanisms of immunosuppression
and why some persons are at higher risk than others remain unclear. Moreover, the absence of
effective human VL vaccines remains a critical gap in preventing disease and improving out-
comes for this group of patients.
The lack of curative, sterilising therapy points the solution on the development of new,
more effective, and less toxic oral drugs coupled with the finding of prognostic biomarkers for
early detection of relapse. The development of safe immunotherapy, as recently proposed,
seems to be an additional option [94]. Finally, the stabilisation and even increase of HIV trans-
mission in many parts of the world, the advancements in organ transplantation techniques,
the persistence of hunger and malnutrition in a scenario of globalisation and global warming,
and the expansion and reemergence of VL in parts of the world like South America [95],
Madrid [32], and Tbilisi [96] raise red flags and stress the priority to be given to this growing
global health challenge.
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